1. Immunotherapy

2. Program Goals

3. Innate and Adaptive Immunity

4. Tumor Cells Are Not "Self"

5. Two Signals for T-Cell Activation

6. Receptors Control T Cell Function

7. Immunity in Tumor Control

8. Tumor Control: Immune Cell Deactivation

9. Immunotherapy Strategies

10. Incidence of ALL

11. ALL: Outcomes in Adults and Children

12. B Cell Surface Antigens

15. Blinatumomab Clinical Results

16. Toxicities of Special Interest in Patients Treated With Blinatumomab

17. Toxicities With Blinatumomab

18. Revised CRS Grading System

19. Overall Survival in Pediatric Blinatumomab Trial*

20. Immune-Checkpoint Axis: Maintains Self-Tolerance and Prevents Autoimmunity

21. PD-1/PD-L1 Pathway Signaling

22. PD-1/PD-L1 Pathway

23. PD-1/PD-L1 in the Immune Response

25. Pathogenesis of Hodgkin Lymphoma

26. Ongoing Clinical Trials in Hematologic Malignancies

27. Nivolumab in HL

29. Pembrolizumab in cHL After BV Failure (KEYNOTE-013)

30. KEYNOTE-013: Tumor Size Change From Baseline

32. Summary and Questions